Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years or older)~* Hematologic malignancy diagnosis or stem-cell transplant recipient~* Eligible for PJP prophylaxis therapy at time of enrollment as per institutional guidelines in compliance with NCCN guidelines. These patients include:~* Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory)~* Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab)~* Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens~* Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis~* Patients who have received an allogeneic stem cell transplant~* Have given informed consent~* May have previously received inhaled or IV pentamidine~Exclusion Criteria:~* Pregnancy~* Prisoners~* Patients with a documented allergy or hypersensitivity to pentamidine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV pentamidine (Type: None): Pentamidine 4mg/kg IV every month (maximum 300mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).